Search
Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Cipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigationalGABA-A receptors, similar to the previously approved [propofol]. … Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated
Alprenolol
go.drugbank.com/drugs/DB00866ApprovedWithdrawnAlprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. … One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.
Zileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnBoth the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. … These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients.
Synonyms: N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea, N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyureaEnmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigationalEnmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. … [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.
Poa pratensis pollen
go.drugbank.com/drugs/DB10366ApprovedPoa pratensis pollen is mainly used in allergenic testing.
Products: Center-AL - Poa Pratensis PollenMacimorelin
go.drugbank.com/drugs/DB13074ApprovedIn clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability [A31481]. … Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD).
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalIn a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295]. … In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of [DB01128] or [DB08899].
Acebutolol
go.drugbank.com/drugs/DB01193ApprovedInvestigationalA cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. … The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Synonyms: N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamideProducts: Penta-acebutolol TabletsEntecavir
go.drugbank.com/drugs/DB00442ApprovedInvestigationalEntecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine … Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Products: ENTECAVIR AL 1MG, ENTECAVIR AL 0.5MG